Hepatitis B viral resistance: Mechanisms and diagnosis

Journal of Hepatology

Volumn 39, Issue SUPPL. 1, 2003, Pages

  Locarnini, Stephen ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; CLEVUDINE; DNA POLYMERASE; LAMIVUDINE; PENCICLOVIR; POL PROTEIN; VIRUS ENVELOPE PROTEIN;

CONFERENCE PAPER; CROSS RESISTANCE; DRUG SENSITIVITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MUTATION RATE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRAL GENETICS; VIRUS DETECTION; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 0141860837     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(03)00318-0     Document Type: Conference Paper

References (93)

1. Richman DD. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 2000;32:866-867.
2. Doo E, Liang JT. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 2001;120:1000-1008.
3. Wolters LM, Niesters HG, Hansen BE, van der Ende ME, Kroon FP, Richter C, et al. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol 2002;24:173-181.
4. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother 2001;12:67-71.
5. Puchhammer-Stockl E, Mandl CW, Kletzmayr J, Holzmann H, Hofmann A, Aberle SW, et al. Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy. J Infect Dis 2000;181:2063-2066.
6. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-180.
7. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-1532.
8. Zollner B, Petersen J, Schroter M, Laufs R, Sehoder V, Feucht HH. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001;357:934-935.
9. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994;198:489-503.
10. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001;33:751-757.
11. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-713.
12. Tipples A, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-717.
13. Bartholomew M, Jansen R, Jeffers L, Reddy K, Johnson L, Bunzendhl H, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-22.
14. Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000;38:702-707.
15. Delaney IV WE, Locaruini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir Chem Chemother 2001;12:1-35.
16. Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T, et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2′ -fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother 2001;45:2495-2501.
17. Harrigan PR, Salim M, Stammers DK, Wynhoven B, Brumme ZL, McKenna P, et al. A mutation in the 3′ region of the human immunodeficiency virus type I reverse transcriptase (Y318F) associated with non-nucleoside reverse transcriptase inhibitor resistance. J Virol 2002;76:6836-6840.
18. Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol 1999;59:270-276.
19. Delaney IV WE, Edwards R, Colledge D, Shaw T, Torresi J, Miller TG, et al. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother 2001;45:1705-1713.
20. King RW, Ladner SK, Miller TJ, Zaifert K, Perni RB, Conway SC, et al. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2f,3Ldideoxy-3Cthiacytidine. Antimicrob Agents Chemother 1998;42:3179-3186.
21. Delaney IV WE, Edwards R, Colledge D, Shaw T, Furman P, Painter G, et al. The phenylopropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother 2002:46:3057-3060.
22. Colledge D, Shaw T, Bowden S, Locaruini S, Lewin S, Wightman F, et al. The purine nucleotide analogue LY582563 (mcc-478) inhibits replication of wild type and drug resistance hepatitis B virus. J Hepatol 2002;36:307A.
23. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996;93:4398-4402.
24. Zeuzem S, de Man RA, Honkoop P, Roth WK, Schalm SW, Schmidt JM. Dynamics of hepatitis B virus infection in vivo. J Hepatol 1997;27:431-436.
25. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999;29:1863-1869.
26. Lewin S, Ribeiro RM, Walter T, Lau GKK, Bowden DS, Locarnini S, et al. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001;34:1012-1120.
27. Brown JL, Carman WF, Thomas HC. The clinical significance of molecular variation within the hepatitis B virus genome. Hepatology 1992;15:144-148
28. Girones R, Miller RH. Mutation rate of the hepadnavirus genome. Virology 1989;170:595-597.
29. Zhang YY, Summers J. Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections. J Virol 1999;73:3616-3622.
30. Urban S, Fischer KP, Tyrrell DL. Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism. Proc Natl Acad Sci USA 2001;98:4984-4989.
31. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998;27:1711-1716.
32. Melegari M, Scaglioni PP, Wands JR, Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication. J Virol 1998;72:1737-1743.
33. Fu L, Cheng YC. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem Pharmacol 1998;55:1567-1572.
34. Ono-Nita SK, Kato N, Shiratori Y, Lan K-H, Yohida H, Carrilho FJ, et al. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999;103:1635-1640.
35. Liaw Y-F, Chien R-N, Yeh C-T, Tsai S-L, Chu C-M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-572.
36. De Man RA, Bartholomeusz A, Niesters HGM, Zondervan PE, Locaruini S. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B virus: hepatitis B immune globulin escape. Famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol 1998;29:669-675.
37. Darwin C. On the origin of species by means of natural selection, 1859.
38. Kosalaraksa P, Kavlick MF, Maroun V, Le R, Mitsuya H. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay. J Virol 1999;73:5356-5363.
39. Imamichi T, Berg SC, Imamichi H, Lopez JC, Metcalf JA, Falloon J, et al. Relative replication fitness of a high-level 3f-azido-3tdeoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr→Gly) at codon 69. J Virol 2000;74:10958-10964.
40. De Ronde A, van Dooren M, Van der Hoek L, Bouwhuis D, de Rooij E, Van Gemen B, et al. Establishment of new transmissible and drugsensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol 2001;75:595-602.
41. Delaney WET, Isom HC. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology 1998;28:1134-1146.
42. Reardon JE. Human immunodeficiency virus reverse transcriptase. A kinetic analysis of RNA-dependent and DNA-dependent DNA polymerization. J Biol Chem 1993;268:8743-8751.
43. Back N, Nijhuis M, Keulen W, Boucher C, Oude Essink B, van Kuilenburg A, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the transverse transcriptase enzyme. EMBO 1996;15:4040-4049.
44. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991;351:317-320.
45. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998;28:1669-1673.
46. Xiong X, Yang H, Westland C, Zou R, Gibbs C. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 2000;31:219-224.
47. Lanford RE, Notvall L, Beames B. Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells. J Virol 1995;69:4431-4439.
48. Seifer M, Hamatake R, Bifano M, Standring D. Generation of replication competent hepatitis B virus nucleocapsids in insect cells. J Virol 1998;72:2765-2776.
49. Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998;28:3200-3208.
50. Locaruini S, Birch C. Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV infected patients. J Hepatol 1999;30:536-550.
51. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-1419.
52. Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, McCaffrey R, et al. Development of HIV-1 resistance to (-)2′-deoxy-3& primary-thiacytidine in patients with AIDS or advanced AIDS-related complex. Aids 1995;9:351-357.
53. Najera I, Holguin A, Quinones-Mateu ME, Munoz-Fernandez MA, Najera R, Lopez-Galindez C, et al. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995;69:23-31.
54. Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001;34:584-586.
55. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-489.
56. Ho D, Toyoshima T, Mo H, Kempf D, Norbeck D, Chen C. Characterisation of human immunodeficiency virus type I variants with increased resistance to a C2-symmetric protease inhibitor. J Virol 1994;68:2016- 2020.
57. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001;107:449-455.
58. Bock C, Tillmann H, Torresi J, Klempnauer J, Locarnini S, Manns M, et al. HBV polymerase mutants with enhanced replication selected during lamivudine therapy result in sudden onset of liver failure. Gastroenterol 2002;122:264-273.
59. Tillmann HL, Trautwein C, Bock T, Boker KH, Jackel E, Glowienka M, et al. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 1999;30:244-256.
60. Zhang YY, Summers J. Low dynamic state of viral competition in a chronic avian hepadnavirus infection. J Virol 2000;74:5257-5265.
61. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000;64:51-68.
62. Bock CT, Schranz P, Schroder CH, Zentgraf H. Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes 1994;8:215-229.
63. Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minochromosomes. J Virol 1995;69:3350-3357.
64. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in non-dividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997 Dec;71:9392-9399.
65. Dean J, Bowden S, Locaruini S. Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir. Antiviral Res 1995;27:171-178.
66. Colledge D, Civitico G, Locarnini S, Shaw T. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob Agents Chemother 2000;44:551-560.
67. Wang Y, Luscombe C, Bowden S, Shaw T, Locarnini S. Inhibition of duck hepatitis B virus DNA replication by antiviral chemotherapy with ganciclovir-nalidixic acid. Antimicrob Agents Chemother 1995;39:556-558.
68. Dandri M, Burda MR, Will H, Petersen J. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology 2000;32:139-146.
69. Delmas J, Schorr O, Jamard C, Gibbs C, Trepo C, Hantz O, et al. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob Agents Chemother 2002;46:425-433.
70. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284:825-829.
71. Bartholomeusz A, Groenen L, Locarnini SA. Clinical experience with famciclovir against Hepatitis B virus and development of resistance. Intervirology 1997;40:337-342.
72. Bartholomeusz A, Schinazi R, Locarnini S. Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling chronic disease. Viral Hepatitis Rev 1998;4:167-187.
73. Poch O, Sauvaget I, Delarue M, Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. Eur Mol Biol Organisation 1989;8:3867-3874.
74. Sarafianos SG, Das K, Clark AD, Ding J, Boyer PL, Hughes SH, et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc Natl Acad Sci USA 1999;96.
75. Gao H-Q, Boyer P, Sarafianos S, Arnold E, Hughes S. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-I reverse transcriptase. J Mol Biol 2000;300:403-418.
76. Huang H, Chopra R, Verdine GL, Harrison SC. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998;282:1669-1675.
77. Jacobo-Molina A, Ding J, Clark AD, Lu X, Tantillo C, Williams RL, et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci USA 1993;90:6320-6324.
78. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterisation of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-1677.
79. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001;75:4771-4779.
80. Neisters H, Honkoop P, Haasma E, de Man R, Schalm S, Osterhaus A. Identification of more than one mutation in the hepatitis B virus polymerase arising during prolonged lamivudine treatment. J Infect Dis 1998;177:1382-1385.
81. Meyer P, Matsuura S, Mian A, So A, Scott W. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999;4:35-43.
82. Arion D, Kaushik N, McCormick S, Borkow G, Parniak M. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processitivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998;37:15908-15917.
83. Gotte M, Arion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol 2000;74:3579-3585.
84. Locarnini S. Hepatitis B virus surface and polymerase gene variants: potential virological and clinical significance. Hepatology 1998;27:294-297.
85. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis [see comments]. Hepatology 1998;27:213-222.
86. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde KH, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by highdose hepatitis B immune globulin after liver transplantation. Hepatology 1998;27:254-263.
87. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini S, et al. Vaccine induced anti-HBs escape mutants of hepatitis B virus arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002;293:305-313.
88. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-851.
89. Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. Aids 2002;16:131-133.
90. Kane M. Global status of hepatitis B immunization. Lancet 1996;348:696.
91. Holland J, De La Torre H, Steinhauer D. RNA virus populations as quasispecies. Curr Top Microbiol Immunol 1992;176:1-20.
92. Condra JH, Emini EA. Preventing HIV-I drug resistance. Sci Med 1997;4:2-11.
93. Richman D. Antiviral drug resistance: issues and challenges. Chichester: John Wiley and Sons; 1996.